Abstract
There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Current Molecular Medicine
Title: Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB
Volume: 7 Issue: 3
Author(s): Kerstin J. Williams and Ken Duncan
Affiliation:
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Abstract: There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Export Options
About this article
Cite this article as:
Williams J. Kerstin and Duncan Ken, Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB, Current Molecular Medicine 2007; 7 (3) . https://dx.doi.org/10.2174/156652407780598575
DOI https://dx.doi.org/10.2174/156652407780598575 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Benzothiazole-based Compounds in Antibacterial Drug Discovery
Current Medicinal Chemistry Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Current Pharmaceutical Design Synthesis and Antibacterial Properties of Oxazolidinones and Oxazinanones
Anti-Infective Agents in Medicinal Chemistry Microwave-Assisted Synthesis of Pyrazinamide Derivatives: The Coupling Reaction of 3-Chloropyrazine-2-Carboxamide and Ring-Substituted Anilines
Current Organic Synthesis Substituted Imidazole-Pyrazole Clubbed Scaffolds: Microwave Assisted Synthesis and Examined Their <i>In-vitro</i> Antimicrobial and Antituberculosis Effects
Letters in Organic Chemistry Effect of Sulfonamides on the Electrophysical Properties of Bacterial Cells
Anti-Infective Agents Recent Advances of Fluorescent Technologies for Drug Discovery and Development
Current Pharmaceutical Design Increased [11C]Choline Uptake in Bronchioloalveolar Cell Carcinoma with Negative [18F]FDG Uptake. A PET/CT and Pathology Study
Current Radiopharmaceuticals Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19
Combinatorial Chemistry & High Throughput Screening Tuberculosis Deaths Among Populations with High HIV Prevalence
Current Respiratory Medicine Reviews Assessment of Glycoproteins Dynamics from Computer Simulations
Mini-Reviews in Organic Chemistry Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Review of Current Chemoinformatic Tools for Modeling Important Aspects of CYPsmediated Drug Metabolism. Integrating Metabolism Data with Other Biological Profiles to Enhance Drug Discovery
Current Drug Metabolism Antibacterial Drug Discovery in the Post-Genomics Era
Current Drug Targets - Infectious Disorders Recombinant Murine Polyoma Virus-like-particles Induce Protective Antitumour Immunity
Letters in Drug Design & Discovery The Medicinal Chemistry of 3-nitro-1,2,4-triazoles: Focus on Infectious Diseases
Current Topics in Medicinal Chemistry